Bempedoic acid is a lipid-lowering drug used to manage high cholesterol levels. It was developed by Esperion Therapeutics to provide an alternative for patients who cannot tolerate statins. The drug works by inhibiting the enzyme ATP citrate lyase, which plays a key role in cholesterol biosynthesis in the liver. Bempedoic acid demonstrated effectiveness in reducing low-density lipoprotein (LDL) cholesterol during clinical trials. Based on its safety and efficacy, it was approved by the U.S. Food and Drug Administration in 2020. It is marketed under the brand name Nexletol.
The drug is particularly beneficial for patients with hypercholesterolemia or those at risk of cardiovascular disease. Unlike statins, it is activated only in the liver, which helps reduce muscle-related side effects. Bempedoic acid is taken orally, often in combination with other lipid-lowering therapies. Its introduction has expanded treatment options for cholesterol management, especially in statin-intolerant individuals. Ongoing research continues to evaluate its long-term cardiovascular benefits and broader therapeutic potential.
